BioSpace News Archive

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer.

Vitro Diagnostics, Inc., dba Vitro Biopharma, announced its 3rd quarter, ended July 31st 2020, financial results of operations.

Evaxion Biotech, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies and vaccines, announces that it has received DKK 4.8 million in funding from Innovation Fund Denmark for the development of its new RAVEN platform, an integral part of Evaxion’s Adaptive and Intelligent Vaccine for a Rapid Response against Corona Viruses program.

Pfizer Inc. announced that its investigational gene therapy candidate being developed to treat Duchenne muscular dystrophy received Fast Track designation from the U.S. Food and Drug Administration.

Replimune Group Inc. announced that members of its senior management team will present in a fireside chat and host investor meetings at the Chardan Virtual 4th Annual Genetic Medicines Conference being held on October 6, 2020 at 4:45 p.m. ET.

Plus Therapeutics, Inc., announced that its abstract regarding lead investigational drug, Rhenium NanoLiposomes, was accepted to the 2020 Society for Neuro-Oncology Annual Meeting being held virtually on November 19-21, 2020.

Majority of customers to see a reduced or same premium, with a $0 premium plan available in every market and virtual care offered at no cost

Chastity no signs of cancer after undergoing CAR T therapy, short for chimeric antigen receptor T-cell therapy — and is one of the youngest patients to receive this advanced cancer treatment.

On Track to Complete Enrollment in First Quarter 2021 and for Top Line Data in Mid-2021

VYNE Therapeutics Inc. announced that its novel ZILXI™ topical foam, 1.5% will be available on October 1, 2020 by prescription for the treatment of inflammatory lesions of rosacea in adults.